TGFβRI-IN-2
|
|
|
- CAS号:
- 1976038-41-1
- 英文名:
- TGFβRI-IN-2
- 英文别名:
- TP-008;TGFβRI-IN-2;TGFβRI-IN-2;TP008,TP 008;3H-Imidazo[4,5-c]pyridine-3-acetamide, 1-[2-(5-chloro-2-fluorophenyl)-5-methyl-4-pyridinyl]-1,2-dihydro-2-oxo-
- 中文名:
- TGFβRI-IN-2
- 中文别名:
- 化合物 T13139
- CBNumber:
- CB88054559
- 分子式:
- C20H15ClFN5O2
- 分子量:
- 411.82
- MOL File:
- 1976038-41-1.mol
|
|
|
TGFβRI-IN-2化学性质
-
沸点:
-
664.2±65.0 °C(Predicted)
-
|
-
密度:
-
1.450±0.06 g/cm3(Predicted)
-
|
-
酸度系数(pKa):
-
15.82±0.40(Predicted)
-
|
TGFβRI-IN-2性质、用途与生产工艺
TGFβRI-IN-2 (compound 18) 是一种有效的，选择性的和口服活性的激活素样激酶 5 (ALK 5) 抑制剂，pIC50 和 pEC50 值分别为 7.6 和 6.63。TGFβRI-IN-2 在高剂量时会在体内产生心脏毒性。
TGFβRI-IN-2 (compound 18) at 1 μM shows a 31% inhibition of MAP3K2 (MEKK2) with an IC
50
value of 2.2 μM.
TGFβRI-IN-2 (oral administation; 50, 150 and 500 mg/kg; 5 days) induces cardiovascular toxicity characterized by valvular interstitial cell proliferation, neutrophil presence, hemorrhage and fibrin deposition in the heart valves.
|
Animal Model:
|
Rats
|
|
Dosage:
|
50, 150 and 500 mg/kg
|
|
Administration:
|
Oral administation; 50, 150 and 500 mg/kg; 5 days
|
|
Result:
|
Induced cardiovalvulopathy in both the medium and high dose animal groups.
|
TGFβRI-IN-2
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-125851 | TP-008 | | 5 mg | 3348元 |
1976038-41-1, TGFβRI-IN-2 相关搜索:
- 化合物 T13139
- 1976038-41-1
- 3H-Imidazo[4,5-c]pyridine-3-acetamide, 1-[2-(5-chloro-2-fluorophenyl)-5-methyl-4-pyridinyl]-1,2-dihydro-2-oxo-
- TP008,TP 008
- TP-008
- TGFβRI-IN-2
- TGFβRI-IN-2